References
- 1. Hruby A, Hu F. The Epidemiology of Obesity: A Big Picture. Pharmacoeconomics. 2015;33(7):673-689.10.1007/s40273-014-0243-x485931325471927
- 2. Upadhyay J, Farr O, Perakakis N, Ghaly W, Mantzoros C. Obesity as a Disease. Med Clin North Am. 2018;102(1):13-33.10.1016/j.mcna.2017.08.00429156181
- 3. Pi-Sunyer FX. Obesity: criteria and classification. Proc Nutr Soc. 2000 Nov;59(4):505-9.10.1017/S0029665100000732
- 4. Segula D. Complications of obesity in adults: a short review of the literature. Malawi Med J. 2014;26(1):20-24.
- 5. Paley CA, Johnson MI. Abdominal obesity and metabolic syndrome: exercise as medicine?. BMC Sports Sci Med Rehabil. 2018;10:7.10.1186/s13102-018-0097-1593592629755739
- 6. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23(5):469-480.10.1111/j.1464-5491.2006.01858.x16681555
- 7. Boles A, Kandimalla R, Reddy PH. Dynamics of diabetes and obesity: Epidemiological perspective. Biochim Biophys Acta Mol Basis Dis. 2017;1863(5):1026-1036.10.1016/j.bbadis.2017.01.016542987628130199
- 8. American Diabetes Association. Introduction: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2019;43(1):S1-S2.10.2337/dc20-Sint31862741
- 9. IDF Europe members. (2020, February 25). Retrieved October 03, 2020, from https://www.idf.org/our-network/regions-members/europe/members/154-romania.html
- 10. Klop B, Elte J, Cabezas M. Dyslipidemia in Obesity: Mechanisms and Potential Targets. Nutrients. 2013;5(4):1218-1240.10.3390/nu5041218370534423584084
- 11. Schofield J, Liu Y, Rao-Balakrishna P, Malik R, Soran H. Diabetes Dyslipidemia. Diabetes Ther. 2016;7(2):203-219.10.1007/s13300-016-0167-x490097727056202
- 12. Catapano A, Graham I, De Backer G et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37(39):2999-3058.10.1093/eurheartj/ehw27227567407
- 13. Kwok S, Adam S, Ho J et al. Obesity: A critical risk factor in the COVID-19 pandemic. Clin Obes. 2020;e12403. Advance online publication.
- 14. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants. The Lancet. 2016;387(10027):1513-1530.
- 15. Mota M, Dinu I. The Analysis of Prevalence and Incidence of Diabetes Mellitus in Romania. Rom J Diabetes Nutr Metab Dis. 2013;20(2):135-139.10.2478/rjdnmd-2013-0017
- 16. Garawi F, Devries K, Thorogood N, Uauy R. Global differences between women and men in the prevalence of obesity: is there an association with gender inequality?. Eur. J. Clin. Nutr. 2014;68(10):1101-1106.
- 17. Kahn S, Hull R, Utzschneider K. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840-846.10.1038/nature0548217167471
- 18. NCD Risk Factor Collaboration (NCD-RisC). Rising rural body-mass index is the main driver of the global obesity epidemic in adults. Nature. 2019;569(7755):260-264.10.1038/s41586-019-1171-x678486831068725
- 19. Porter Starr KN, Bales CW. Excessive Body Weight in Older Adults. Clin Geriatr Med. 2015;31(3):311-326.10.1016/j.cger.2015.04.001451046726195092
- 20. Johnson MA, Bales CW. Is there a best body mass index for older adults? Moving closer to evidence-based recommendations regarding “overweight,” health, and mortality. J Nutr Gerontol Geriatr. 2014;33(1):1-9.10.1080/21551197.2014.87581724597992
- 21. Flegal KM, Kit BK, Graubard BI. Overweight, obesity, and all-cause mortality--reply. JAMA. 2013;309(16):1681-1682.10.1001/jama.2013.310123613067
- 22. Akhter O, Fiazuddin F, Shaheryar A et al. Central adiposity is significantly higher in female compared to male in Pakistani type 2 diabetes mellitus patients. Indian J Endocrinol Metab. 2015;19(1):72-76.10.4103/2230-8210.131767428778425593830
- 23. Kagawa M, Kerr D, Uchida H, Binns CW. Differences in the relationship between BMI and percentage body fat between Japanese and Australian Caucasian young men. Br J Nutr. 2006;95:1002–100710.1079/BJN20061745
- 24. Segula D. Complications of obesity in adults: a short review of the literature. Malawi Med J. 2014;26(1):20-24.
- 25. Lazarte J, Hegele RA. Dyslipidemia Management in Adults With Diabetes. Can J Diabetes. 2020;44(1):53-60.10.1016/j.jcjd.2019.07.00331521544
- 26. Aslan I, Kucuksayan E, Aslan M. Effect of insulin analog initiation therapy on LDL/HDL subfraction profile and HDL associated enzymes in type 2 diabetic patients. Lipids Health Dis. 2013;12:5410.1186/1476-511X-12-54365369023617853
- 27. Lin SH, Cheng PC, Tu ST, Hsu SR, Cheng YC, Liu YH. Effect of metformin monotherapy on serum lipid profile in statin-naïve individuals with newly diagnosed type 2 diabetes mellitus: a cohort study. PeerJ. 2018;6:e4578.10.7717/peerj.4578
- 28. Zhang L, Zhang WH, Zhang L, Wang PY. Prevalence of overweight/obesity and its associations with hypertension, diabetes, dyslipidemia, and metabolic syndrome: a survey in the suburban area of Beijing, 2007. Obes Facts. 2011;4(4):284-289.10.1159/000331014
- 29. Nguyen NT, Magno CP, Lane KT, Hinojosa MW, Lane JS. Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg. 2008;207(6):928-934.10.1016/j.jamcollsurg.2008.08.022
- 30. Taskinen M, Adiels M, Westerbacka J et al. Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects. Arterioscler Thromb Vasc Biol. 2011;31(9):2144-2150.10.1161/ATVBAHA.111.224808
- 31. Hirano T. Pathophysiology of Diabetic Dyslipidemia. J Atheroscler Thromb. 2018;25(9):771-782.10.5551/jat.RV17023
- 32. Thagele S, Sharma A, Singh N, Kumar M, Rawat D, Sharma S. Impact of Disease Duration on Lipid Profile in Type 2 Diabetes Mellitus Patients. J Med Sci Clin Res. 2018;6(9):697-701.10.18535/jmscr/v6i9.122
- 33. Czech MP. Insulin action and resistance in obesity and type 2 diabetes. Nat Med. 2017;23(7):804-81410.1038/nm.4350
- 34. Herrington W, Alegre-Díaz J, Wade R et al. Effect of diabetes duration and glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based prospective cohort study. Lancet Diabetes Endocrinol. 2018;6(6):455-463.10.1016/S2213-8587(18)30050-0
- 35. Shahwan M, Jairoun A, Farajallah A, Shanabli S. Prevalence of dyslipidemia and factors affecting lipid profile in patients with type 2 diabetes. Diabetes Metab Syndr. 2019;13(4):2387-2392.10.1016/j.dsx.2019.06.00931405648
- 36. Dharmalingam M, Yamasandhi PG. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Indian J Endocrinol Metab. 2018;22(3):421-428.10.4103/ijem.IJEM_585_17606317330090738
- 37. Henning RJ. Type-2 diabetes mellitus and cardiovascular disease. Future Cardiol. 2018;14(6):491-50910.2217/fca-2018-004530409037
- 38. Beigh SH, Jain S. Prevalence of metabolic syndrome and gender differences. Bioinformation. 2012;8(13):613-616.10.6026/97320630008613340098922829741
- 39. Sidorenkov O, Nilssen O, Brenn T, Martiushov S, Arkhipovsky VL, Grjibovski AM. Prevalence of the metabolic syndrome and its components in Northwest Russia: the Arkhangelsk study. BMC Public Health. 2010;10(1):23.10.1186/1471-2458-10-23283277320085638